このページの翻訳は実験的なもので、現在開発中です。 フィードバックを お待ちしております ！
Johnson & Johnson バランスシートの健全性 Johnson & Johnsonの総株主資本は$71.5B 、総負債は$41.5Bで、負債比率は58%となります。総資産と総負債はそれぞれ$181.1Bと$109.6Bです。 Johnson & Johnsonの EBIT は$24.2Bで、利息カバレッジ比率-33.2です。現金および短期投資は$25.5Bです。
主要情報 インタレスト・カバレッジ・レシオ -33.2x 現金 US$25.48b エクイティ US$71.54b 負債合計 US$109.55b 総資産 US$181.09b
財務の健全性に関する最新情報
すべての更新を表示 Johnson & Johnson Announces Interim Data from the Ongoing Phase 2 Sunrise-4 Study Showing Neoadjuvant Treatment with Investigational Tar-200 Plus Cetrelimab Johnson & Johnson Announces Updated Results from the Phase 3 Mariposa-2 Study Which Showed Rybrevant (Amivantamab-Vmjw) Sep 14
Johnson & Johnson Announces the Retirement of D. S. Davis as Director and Committee Changes Sep 11
Johnson & Johnson to Report Q4, 2024 Results on Jan 22, 2025 Sep 06
Johnson & Johnson Seeks First Approval of Nipocalimab to Treat Broadest Population Living with Antibody Positive Generalized Myasthenia Gravis Aug 29
Johnson & Johnson Announces Executive Changes Aug 26
Johnson & Johnson Announces U.S. Food and Drug Administration Approves Rybrevant® (Amivantamab-Vmjw) Plus Lazcluze™ (Lazertinib) Aug 20
Johnson & Johnson Announces Results from the Phase 2 Open-Label UNITY Study of Nipocalimab for the Treatment of Alloimmunized Pregnant Individuals Aug 08
Johnson & Johnson Announces Darzalex Faspro® (Daratumumab and Hyaluronidase-Fihj)-Based Quadruplet Regimen Approved in the U.S. for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible Aug 01
Johnson & Johnson Seeks U.S. FDA Approval of Spravato (Esketamine) as the First and Only Monotherapy for Adults with Treatment-Resistant Depression Jul 22
Second quarter dividend of US$1.24 announced Jul 19 Johnson & Johnson Announces Quarterly Cash Dividend for Third Quarter of 2024, Payable on September 10, 2024 Jul 17
Johnson & Johnson Announces Positive Results from Prespecified Second Interim Analysis of the Phase 3 CARTITUDE-4 Study Evaluating CARVYKTI Jul 03
Johnson & Johnson Announces Positive Results from the Nipocalimab Phase 3 Vivacity-MG3 Study Jun 28
Johnson & Johnson (NYSE:JNJ) completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million. Beasley Allen and Levin Papantonio Announces Class Action Lawsuit Against Johnson & Johnson Johnson & Johnson Announces TALVEY® (Talquetamab-Tgvs) Demonstrates Highly Durable, Longer-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma
New major risk - Revenue and earnings growth Jun 09 Johnson & Johnson to Report Q3, 2024 Results on Oct 15, 2024 Jun 06
Johnson & Johnson Announces Results from a Subgroup Analysis of the Phase 3 CARTITUDE-4 Study
財務状況分析
短期負債: JNJの 短期資産 ( $57.8B ) が 短期負債 ( $53.9B ) を超えています。
長期負債: JNJの短期資産 ( $57.8B ) が 長期負債 ( $55.6B ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: JNJの 純負債対資本比率 ( 10.6% ) は 満足できる 水準であると考えられます。
負債の削減: JNJの負債対資本比率は、過去 5 年間で48.4%から58%に増加しました。
債務返済能力: JNJの負債は 営業キャッシュフロー によって 十分にカバー されています ( 69% )。
インタレストカバレッジ: JNJ支払う利息よりも稼ぐ利息の方が多いので、 利息支払い の補償は問題になりません。
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.